This model effectively captures constitutive MAPK/ERK hyperactivation but may not fully represent the genetic heterogeneity observed in patient cohorts, where BRAF V600E often coexists with heterozygous mutations, additional oncogenic drivers (e.g., NRAS or PTEN alterations), or variable tumor subclones. Here, BRAF is linked to neoplasm.